BioSpace News Archive

Many biopharma companies raised funds in 2022, but not enough to reach their next milestone. Investors have been constricting investments, so companies needing additional funding require a larger toolbox.

Hemispherian AS, a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce the closure of the first tranche of its series A1 financing round.

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has submitted a marketing authorization application to the United Kingdom’s Medicines and Healthcare products Regulatory Agency for toripalimab.

A clinical study to explore the influence of BR1 on rheumatoid arthritis conducted by Professor Gregory J. Tsai from China Medical University Hospital in Taiwan was published at a meeting of the American Association of Immunologist, a top medical society in the US.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 11,400 shares of the Company’s common stock at an exercise price per share of $27.17, which was the closing price on November 23, 2022, and restricted stock units to acquire a total of 5,700 shares of the Company’s common stock.

Kane Biotech Inc. announced its third quarter 2022 financial results.

With the FDA Modernization Act’s passage earlier this year, drug developers have the opportunity to forgo animal models in preclinical development for the first time in history.

Revive Therapeutics Ltd. announced that it will submit the Type C meeting request package to the US FDA by mid-December 2022, which will outline the overall development plan and Pre-Dose selection data supporting the latest revised endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

XtalPi announced that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group.

Medicure Inc. reported its results from operations for the quarter ended September 30, 2022.